top of page

Research Pipeline...

EndoProtech has an additional patent for a therapy to treat inflammation in alcoholic liver disease. The company has developed a product to the proof-of-concept stage. The therapy to treat alcoholic liver disease has demonstrated efficacy in pre-clinical studies using a mouse model of alcoholic liver disease.

A Novel Approach to Reduce Infarct Size Following Myocardial Infarction

EndoGuard: Is a novel therapy designed to treat cardiac microvascular obstruction ("no-reflow" phenomenon) following revascularization of the occluded coronary artery. Preclinical studies have demonstrated that intracoronary administration of EndoGuard just before reperfusion reduced myocardial infarct size by ~50% and the area of "no-reflow by ~85%. The drug is indicated for use as an adjuvant to percutaneous coronary intervention (PCI) to treat patients with ST segment-elevation myocardial infarction (STEMI).

Looking at Liver Disease a Whole New Way

Endohepal: Is a liposomal-rolipram therapy designed to treat alcoholic hepatitis while reducing the well-known side effects that phosphodiesterase 4 inhibitors produce. Preclinical studies have demonstrated the ability of the drug to reduce liver inflammation and alcohol-related steatosis.

Related Publications and Research:

pdf.png

Stabilizing the endothelium of donor hearts with

fusogenic liposomes reduces myocardial injury and dysfunction

​

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC3619012/

pdf.png

Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis

​

​

​

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC9078351/pdf/dddt-16-1301.pdf

pdf.png

Enhancing complement control on endothelial barrier

reduces renal post-ischemia dysfunction

​

​

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC3175310/

pdf.png

Rapid Lipid Modification of Endothelial Cell Membranes in Cardiac Ischemia/Reperfusion Injury: a Novel Therapeutic Strategy to Reduce Infarct Size

​

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC8376233/pdf/nihms-1730159.pdf

pdf.png

A novel liposome-based therapy to reduce complement-mediated

injury in revascularized tissues

​

​

​

Link: www.ncbi.nlm.nih.gov/pmc/articles/PMC3005705/

Patents

Cell-surface Decoration with Active Agents: Japanese Patent No. 5264478; New Zealand Patent No. 562946; Australian Patent No. 2006 242354; Canadian Patent No. 2,605,863; Great Britain Patent No. 1877038, Germany Patent No. 602006052042.5, and France Patent No. 1877038. Treating Microvascular Dysfunction: US Patent No. 11,590079.

bottom of page